

September 4, 2018



Ensysce Biosciences to Present Novel TAP Opioid Technology at 7th Annual Gateway Investor Conference September 5, 2018

The promise of protection from opioid abuse.

SAN DIEGO--(BUSINESS WIRE)-- Ensysce Biosciences, Inc., an integrated drug delivery company for both small and large molecules, today announced that D. Lynn Kirkpatrick, Ph.D., Chief Executive Officer, will present at the upcoming 7th Annual Gateway Conference, 'Overcoming Drug Abuse, Misuse and Overdose'. The Conference is being held September 5-6, 2018, at the Four Seasons, San Francisco, California. Dr. Kirkpatrick will discuss the company's TAP opioid abuse and overdose protection technologies that can help to prevent the serious problems of drug misuse and overdose. Further information on details on the Gateway Conference can be found [here](#).

Dr. Kirkpatrick will highlight advances in Ensysce's Trypsin Activated Prodrug (TAP) platform that delivers safer opioid analgesics with the promise of true overdose protection. The opioid crisis in America is growing and abuse deterrent formulations have proved ineffective in curbing the epidemic. The goal of the TAP opioid platform is to provide an effective and truly abuse proof alternative. TAP products are activated in the digestive system, eliminating the ability to abuse and misuse opioid, ADHD and other prescription drugs by chewing, inhalation or manipulation and injection. Ensysce's lead product, PF614, an extended release TAP oxycodone, has received Fast Track Status from the FDA and is quickly moving through clinical development.

About Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is an integrated drug delivery company for both small and large molecules. To overcome the major problem of non-medical use of opioid products, Ensysce is using its prodrug technology to improve abuse deterrent properties. The TAP BIO-MD™ abuse deterrent and MPAR™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. This abuse is the fastest growing drug problem in the U.S. and it leads to billions in healthcare costs annually. For additional information about Ensysce Biosciences please visit www.ensysce.com.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20180904005025/en/>

Ensysce Biosciences Inc.

D. Lynn Kirkpatrick, Ph.D., 858-242-1553

CEO

lkirkpatrick@ensysce.com

Source: Ensysce Biosciences Inc.